Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Entera Bio Ltd. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 18 | 19 | +1 |
| Shares | 10.2M | 10.2M | −11.3K (−0.1%) |
| Value | $17.4M | $19.4M | +$2.02M (+11.6%) |
New holders (4)
Institutions that held Entera Bio Ltd. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bessemer Group Inc | 140,843 | $268.0K | 0.00% |
| UBS Group AG | 15,631 | $29.7K | 0.00% |
| Citadel Advisors LLC | 11,656 | $22.1K | 0.00% |
| Jane Street Group, LLC | 10,187 | $19.4K | 0.00% |
Sold out (3)
Institutions that held Entera Bio Ltd. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Perigon Wealth Management, LLC | 145,843 | $247.9K |
| Two Sigma Securities, LLC | 12,554 | $21.3K |
| XTX Topco Ltd | 10,859 | $18.5K |